Status:
TERMINATED
Nesiritide and Renal Function After the Total Artificial Heart
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Congestive Heart Failure
Cardiorenal Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH...
Detailed Description
This is a randomized, double blinded placebo controlled study that will take place in the Cardiac Surgery Intensive Care Unit, at Virginia Commonwealth University (VCU) Hospital Center. This study wi...
Eligibility Criteria
Inclusion
- Implanted with a total artificial heart (CardioWest) or Left ventricular assist device (HeartMate II)
- Age \> 18 years
Exclusion
- Previous calcineurin inhibitor (CNI) exposure
- Hemodialysis prior to device implant
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01836809
Start Date
April 1 2013
End Date
May 1 2014
Last Update
February 8 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298